Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Moleculin Biotech Inc (MBRX): Proceed With Caution

Page 1 of 3

Moleculin Biotech Inc (NASDAQ:MBRX), an oncology-focused pharmaceutical firm that just joined public markets in June, is making some waves in the biotech world. Having initially traded above issue to raise $9.2 million and reach post-IPO highs just shy of $9, the company has since settled into the $6-7 range. It’s targeting the development of an interesting asset in the oncology space, but it’s also running a pretty aggressive $20,000 promotional campaign according to HotStocked. These sorts of promotional campaigns can sometimes be legitimate advertising for a company looking for real investors and that’s OK, but they can also be red flags due to conflicts of interest that ensue.

Confirming this is a disclaimer that came from this newsletter, sent out by Small Cap Leader. Moleculin paid this company $20,000 to push its stock on its email subscribers. There are two more – Awesome Stocks here and Stock Trade Wire – for which compensation is not disclosed.

What matters, though, is what’s under the hood. With this in mind, let’s have a look at what Moleculin has to offer investors in an attempt to determine whether or not its fundamentals support its current market cap of circa $75 million.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

RAJ CREATIONZS / shutterstock.com

 First up, a look at the drug. It’s called Annamycin, and it’s a version of an already approved and very widely used chemotherapy drug type called anthracycline, of which the drug doxorubicin, brand name Doxil by Johnson & Johnson (NYSE:JNJ), is the best known and best selling. Anthracyclines are used to treat most types of cancer, and through inhibiting DNA synthesis among other means they stop cancerous cells from replicating. The problem with anthracyclines, however, is they have an extremely high cardiotoxicity. This limits their efficacy, as dosing is limited to how much a patient (and in particular, a patient’s heart) can withstand. Annamycin is a liposomal version of anthracycline, meaning it is enveloped in a pocket like a cell membrane, which reduces toxicity by preventing direct exposure. This reduces the cardiotoxicity of the drug, which increases the potential dosing, and in turn, should translate to an improved efficacy.

On top of reduced cardiotoxicity, the liposomal element of Annamycin also “hides” it from the multidrug resistance-associated protein (MRP). This protein sits at the outer layer of cancerous cells. When a patient undergoes chemotherapy, the chemo will kill some cells, but leave others that are resistant to the treatment as a result of them expressing this MDR protein, in a survival of the fittest cancer cells mechanism. This means the resistant cells are left to replicate, so when the same treatment is used again, MDR protein pumps recognize the chemo compound and literally pump it out of the cell, negating its efficacy. Multiple studies have shown that these MDR pumps are not able to recognize Annamycin, which eliminates the potential for resistance at least from that factor.

Moleculin is going after a second line acute myeloid leukemia (AML) indication. In patients with AML, the goal is to reduce the number of cancerous cells to the lowest level possible, and then to do a bone marrow transplant. In as many as 80% of treated patients, however, it’s not possible to reduce to the 95% degree required before a bone marrow transplant, and this is in part due to the dose limiting toxicity of anthracyclines drugs. Moleculin is hoping that it can improve the rate of patients that become eligible for a bone marrow transplant with its high dose, low toxicity version of anthracycline.

The hypothesis is sound, and the science is supported by data, but there are some issues.

The first is that the drug isn’t yet technically eligible for investigational development. Moleculin bought the rights to the drug last year from a private entity called AnnaMed. AnnaMed had discontinued the development of the drug, and so the IND on which this development rested expired. So, to start any clinical trials going forward, the company has to get a fresh IND, a complex bureaucratic process.

Before this, it has to audit the results that AnnaMed derived from its preclinical and clinical trials of the drug, and verify they are correct. Now, there shouldn’t be any issue there, but it’s a cost and time factor. IND submissions cost around $600K, and since the company is applying for a special protocol assessment which will allow it to use a phase IIb as a pivotal trial) it could be months before it’s even allowed to start its own development of Annamycin.

Page 1 of 3

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!